Latest news with #Gaithersburg
Yahoo
a day ago
- Business
- Yahoo
Longhorn Vaccines and Diagnostics Partners with Promega to Combine Complementary Offerings for Enhanced Sample Collection, Transport and Analysis
Longhorn's validated PrimeStore® MTM sample collection device and Promega Maxwell® instruments will be offered together to laboratories globally Longhorn and Promega to showcase combined offering at the Association for Diagnostics & Laboratory Medicine conference, July 29-31, 2025 BETHESDA, Md. & GAITHERSBURG, Md., July 28, 2025--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced a strategic co-marketing agreement with Promega Corporation to deliver integrated molecular testing solutions designed to enhance safety, efficiency and flexibility across a wide range of diagnostic settings. This collaboration brings together Longhorn's validated PrimeStore® Molecular Transport Medium (MTM) and Promega's Maxwell® automated nucleic acid extraction platform, delivering a powerful, end-to-end workflow to support an all-in-one solution for safer and enhanced virus sample collection, transportation and analysis. Longhorn's PrimeStore® MTM is an inactivating molecular transport medium for both RNA and DNA. The device delivers nucleic acid samples in a time-efficient manner with Promega's Maxwell® instruments and reagent kits, designed for the automated extraction of viral total nucleic acid from a range of sample types. "The accuracy of molecular diagnostics, PCR and sequencing, starts with high quality nucleic acid," said Longhorn Vaccine and Diagnostics President Jeff Fischer. "Promega has proven that PrimeStore® MTM does just that with validation testing on their Maxwell® platform. Samples are safe to handle outside of containment, speeding up the testing time and therefore speeding up the accurate treatment of patients. The Maxwell® platform and nucleic acid extraction kits are now being added to our Instructions for Use." "Together, these technologies streamline the workflow from sample collection to high-quality nucleic acid purification without compromising on safety or performance," said Promega Director of Applied Markets Julie Yang. Longhorn and Promega will showcase their combined technologies at the upcoming Association for Diagnostics & Laboratory Medicine conference (ADLM 2025) in Chicago from July 29-31, 2025. Visit booth #3757 to learn more about PrimeStore® MTM and booth #3655 to learn more about the Maxwell® instruments and nucleic acid purification kits. A joint poster showcasing how these technologies work together was presented at the May 2025 Association of Public Health Laboratories annual conference in Portland, Oregon, titled "Validation of a Novel Sample Collection-to-Detection Workflow Using PrimeStore® MTM, Pathogen Total Nucleic Acid Kit, and PrimeMix® MTB." A second joint poster was presented at the June 2025 International Symposium of the World Association of Veterinary Laboratory Diagnosticians conference in Calgary, Alberta, titled "Novel Biosafe and Scalable Detection of Influenza A (H5N1, H3N2, H1N1) for Veterinary and One Health Applications." For more information about Longhorn, visit About Longhorn Vaccines and DiagnosticsLonghorn Vaccines and Diagnostics is a closely held One Health company based in Maryland that is developing broad coverage vaccines and diagnostic tools for worldwide public health concerns such as anti-microbial resistance, sepsis and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing broad coverage vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn products play a significant role to surveil, diagnose, prevent and treat the next infectious disease. Longhorn's core diagnostic product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. About Promega CorporationPromega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. View source version on Contacts Longhorn Vaccines and DiagnosticsJeffrey FischerEmail: jeff@ MediaAlexis Feinberg – ICR HealthcareEmail: Promega CorporationPenny PattersonE-mail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
5 days ago
- Business
- Globe and Mail
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025. Management will host a conference call and webcast at 8:30am EDT/13:30pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus' website. About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL ®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit
Yahoo
5 days ago
- Health
- Yahoo
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. "These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for partnership and prioritizing areas of unmet medical need, including vaccines for avian pandemic influenza, where we see clear potential advantages for our technology compared with other vaccines that are licensed or in development." Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. These data suggest that even a single IN dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza either by vaccination or infection. Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of the H5N1 virus. H5N1, a highly pathogenic and dynamic avian pandemic influenza virus, is of concern due to its potential to mutate into a strain adapted for sustained human-to-human transmission. To date, there have been 70 confirmed total reported human cases in the U.S., and one death associated with H5N1 avian pandemic influenza infection.1 As of July 2025, no reported cases in the U.S. have been proven to result from human-to-human transmission. As part of its corporate growth strategy, Novavax is making targeted investments in early-stage development programs to create value. Novavax intends to pursue funding, partnership and licensing opportunities for its H5N1 vaccine candidate. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development (R&D) innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for a single intranasal or intramuscular dose differentiating Novavax's H5N1 vaccine, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler (844) 264-8571 media@ References U.S. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. 2025. Available at: View original content to download multimedia: SOURCE Novavax, Inc.
CBS News
6 days ago
- CBS News
Former FBI agent found guilty of rape, luring victims to Maryland tattoo shop
A former FBI agent convicted of rape faces up to 122 years in prison, according to the Montgomery County State's Attorney Office. Eduardo Valdivia was found guilty on six counts of second-degree rape and two counts of fourth-degree sex offense, after sexually assaulting three young women at his Gaithersburg tattoo shops. Valdivia, 41, of Gaithersburg, was arrested in November 2024 after the first victim told police in October that she was raped by someone she knew as "Lalo Brown." At the time of his arrest, Valdivia had been a supervisory special agent with the Federal Bureau of Investigation for over a decade. He owned a tattoo studio, DC Fine Line Tattoos, in the 9800 block of Washingtonian Boulevard in Gaithersburg. In November 2024, a second victim came forward with a similar report of sexual assault, according to police. Both women, in their early 20s, reported they were lured to the tattoo studio under the pretense of modeling opportunities with Exeter Models. Following news of his arrest, a third victim came forward and disclosed that she had been raped by Valdivia in October 2022 at a tattoo studio in the 12000 block of Travilah Road in Potomac. She said was 18 years old at the time. Valdivia communicated with the victims under aliases including "Lalo Brown" and "L. Boogie," luring them to the tattoo studios under the pretense of free tattoos and modeling opportunities, according to prosecutors. He also used the alias "Dr. Tiffany Kim," pretending to be a female psychologist and the CEO, president, and producer of a profitable and well-connected modeling agency in email communications with two of the victims, the State's Attorney's Office said. Valdivia faces a maximum sentence of 122 years in prison. A sentencing hearing is scheduled for October 14, 2025.
Yahoo
26-06-2025
- Business
- Yahoo
GL Enhances 100G Ethernet Testing for High-Speed Networks
GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- GL Communications Inc., a global leader in telecom testing solutions, addressed the press regarding their multi-port testing for high-speed network environments. As networks continue to grow in speed and complexity, the ability to test multiple ports simultaneously becomes essential. GL's PacketExpert™ 100G enables testing across several high-speed Ethernet ports in parallel. This allows network engineers to verify performance and reliability more efficiently, while also saving space and reducing equipment needs in labs and production setups. [Refer to Vijay Kulkarni, CEO of GL Communications, states, 'GL's PacketExpert™ 100G is a scalable, multi-functional network testing appliance for comprehensive Ethernet and IP testing at speeds up to 100 Gbps. It integrates a high-performance PC with specialized NICs, GL's PacketExpert™ software, and optimized hardware for processing, storage, and cooling. The system supports 1 Gbps, 10 Gbps, 25 Gbps, 40 Gbps, 50 Gbps, and 100 Gbps Ethernet ports, with up to eight ports capable of simultaneous wirespeed traffic generation and reception.' A web-based interface allows multiple users to remotely access and control devices, enabling centralized management of large multi-port test setups. Python scripting further enhances efficiency by enabling repeatable, scalable, and fully remote execution of complex test scenarios. Multi-port testing is essential to validate that devices with multiple high-speed ports can simultaneously handle diverse traffic streams at full line rate without errors or degradation—ensuring reliable, high-density performance in real-world environments. PacketExpert™ 100G supports flexible multi-port configurations using dual 100G ports with breakout cables and adapters. A single 100G port can be split into four 25G ports via a QSFP28 to 4 × SFP28 cable (4 x 25G), while a 40G port can be split into four 10G ports using a QSFP to 4 × SFP+ cable (4 x 10G), enabling simultaneous multi-rate testing without additional hardware. [Refer to Port Settings for 4 x 25G Mode and Port Settings for 4 x 10G Mode] In 4 × 25G or 4 × 10G modes, PacketExpert™ 100G activates four independent ports (Port 1 to Port 4) for concurrent Ethernet interface testing. This setup reduces device and cable requirements, saves rack space, and boosts efficiency in lab and production environments. PacketExpert™ 100G supports up to eight 100G ports in a 4U rack-mount chassis using multiple network interface cards, enabling extensive multi-port scalability. It performs Bit Error Rate Testing (BERT) and RFC 2544 throughput and latency measurements on up to 8 ports for 100G, 50G, 40G, and 1G, and up to 16 ports for 10G and 25G. The platform handles up to 128 unique streams (16 per port), scalable to 256 streams for 10G and 25G, allowing comprehensive ExpertSAM™ (ITU-T Y.1564) service activation testing. With flexible multi-rate port breakout, high-density scalability, and wide stream support, PacketExpert™ 100G is a critical tool for validating multi-port Ethernet performance in demanding network environments. The solution offers a full suite of test applications from physical to transport layers. These include Bit Error Rate Testing for verifying physical link integrity, Smart Loopback Testing for quick link verification, RFC 2544 for standardized benchmarking of throughput, packet loss, latency, and burst performance, ExpertSAM™ (ITU-T Y.1564) for validating SLAs across multiple streams, and Multi-Stream Traffic Generator and Analyzer (MTGA) for simulating and monitoring real-world traffic. These applications support testing across Layer 2 (Ethernet), Layer 2.5 (VLAN or MPLS), Layer 3 (IPv4 or IPv6), and Layer 4 (UDP), ensuring networks are fully prepared for high-speed, multi-service deployments. PacketExpert™ 100G provides advanced support for SyncE, enabling precise clock synchronization validation in high-speed Ethernet networks. It continuously monitors the incoming clock's Quality Level using background heartbeat messages and instantly flags any degradation—crucial for time-sensitive applications like mobile backhaul, data centers, and industrial networks. Using Precision Time Protocol (PTP), PacketExpert™ 100G synchronizes accurately with the network's master clock, ensuring proper time alignment across devices. This is essential for timing-critical tests such as RFC 2544 latency and ExpertSAM™ SLA validation, delivering reliable and repeatable delay and jitter measurements in complex Ethernet and IP environments. PacketExpert™ 100G includes robust Python APIs for automation and regression testing, ideal for continuous integration workflows. Users can remotely configure ports, run tests like BERT, RFC 2544, and Y.1564, and collect results programmatically. The platform supports parallel test execution across multiple ports and devices (1G to 100G), with real-time result monitoring and alerting—ensuring fast, repeatable, and fully automated validation of high-speed Ethernet networks. [Refer to Multi-port Python Script] About GL Communications Inc., GL Communications is a global provider of telecom test and measurement solutions. GL's solutions verify the quality and reliability of Wireless, Fiber Optic, TDM and Analog networks. Warm Regards, Vikram Kulkarni, PhD Phone: 301-670-4784 x114 Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
